4D pharma to Present at the H.C. Wainwright BioConnect Conference
05 Gennaio 2022 - 1:00PM
Business Wire
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical
company leading the development of Live Biotherapeutic products
(LBPs), a novel class of drug derived from the microbiome, today
announced that Duncan Peyton, Chief Executive Officer of 4D pharma,
and Alex Stevenson, Chief Scientific Officer of 4D pharma, will
present at the H.C. Wainwright BioConnect Conference. The
presentation will be available for on-demand viewing starting
Monday, January 10, 2022 at 7:00 a.m. ET (12:00 p.m. GMT).
A replay webcast of the presentation will be available via the
‘Events’ section of the 4D pharma website at www.4dpharmaplc.com
for 90 days following the presentation.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D pharma has developed a proprietary platform,
MicroRx®, that rationally identifies Live Biotherapeutics based on
a deep understanding of function and mechanism.
4D's Live Biotherapeutic Products are orally delivered single
strains of bacteria that are naturally found in the healthy human
gut. The Company has six clinical studies in progress, namely a
Phase II clinical study of Blautix® in Irritable Bowel Syndrome
(IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA®
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, and a Phase I/II
study of MRx-4DP0004 in asthma. Preclinical-stage programs include
candidates for CNS disease such as Parkinson's disease and other
neurodegenerative conditions. The Company has a research
collaboration with MSD, a tradename of Merck & Co., Inc.,
Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics
for vaccines.
For more information, refer to https://www.4dpharmaplc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220105005019/en/
4D Duncan Peyton, Chief Executive Officer +44 (0)113 895
0130 Investor Relations ir@4dpharmaplc.com
Singer Capital Markets - Nominated Adviser and Joint
Broker +44 (0)20 7496 3000 Philip Davies / James Fischer
(Corporate Finance) Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20
7332 2500 Dominic Wilson
Stern Investor Relations Julie Seidel +1-212-362-1200
Julie.seidel@sternir.com
Image Box Communications Neil Hunter / Michelle Boxall
+44 (0)20 8943 4685
6 Degrees Lynne Dardanell +1-336-202-9689
ldardanell@6degreespr.com
Grafico Azioni 4D Pharma (NASDAQ:LBPS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni 4D Pharma (NASDAQ:LBPS)
Storico
Da Set 2023 a Set 2024